Mylan (NDSQ:MYL) declined to testify at a U.S. Senate committee regarding its $465 million pending settlement to deal with charges that it underpaid government healthcare programs when it misclassified its EpiPen injector as a generic.
The Canonsburg, Pa.-based company penned a letter to the Senate Judiciary Committee Nov. 18, saying it would not testify because the matter of its settlement with the government is still pending.
Get the full story at our sister site, Drug Delivery Business News
The post Mylan declines to testify at Senate committee hearing appeared first on MassDevice.
from MassDevice http://ift.tt/2gi5eVK
Cap comentari:
Publica un comentari a l'entrada